← FDA Drug Approvals (Drugs@FDA)

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: CHARTWELL RX · Approved 2023-10-03

Drug application

FDA Application #
ANDA201802
Application type
Abbreviated New Drug Application (Generic)
Brand name
EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Generic name
Efavirenz
Active ingredients
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Dosage form
TABLET
Route
ORAL
Marketing status
Prescription
Sponsor
CHARTWELL RX
First approval
2023-10-03

Source

Authoritative
Drugs@FDA application overview
Machine
JSON-LD · Markdown